Innovation in Cell Death Research, Volume 217 covers topics relating to the identification of unique signaling pathways, the discovery of biomarkers and innovative treatment strategies, neurodegenerative diseases, and immune-related disorders. Chapters in this new release include Cell Death Triad: Integrating Apoptotic, Autophagic, and Necrotic Cell Death Mechanisms, Advances in Cell Death Detection and Imaging, Informatic and data science for the cell death researches, Visualizing and Mapping Cell Death: Biochemical Tools, Techniques and Assays, and the Role of Autophagy in Cell Death and Survival: Mechanisms and Therapeutic Implications.
Other sections cover the Role and Relation of Cell Death in Cancer Disease, Exploring Pyroptosis: From molecular mechanisms to cancer therapeutics, Current findings and potential applications of cell death research in ovarian cancer, PHAGEPTOSIS: A BACTERIAL CELL DEATH PROGRAM INDUCED BY CRISPR-CAS SYSTEMS, Cell death mechanisms in Drosophila: Responses to infectious challenges, and much more.
- Covers topics relating to the identification of unique signaling pathways
- Presents the latest on cell-death, with chapters such as Cell Death Triad: Integrating Apoptotic, Autophagic, and Necrotic Cell Death Mechanisms, and Advances in Cell Death Detection and Imaging
- Elucidates on the role and relation of Cell Death in Cancer
Dr. Vijay Kumar Prajapati is an Associate Professor in the Department of Biochemistry at the University of Delhi South Campus, New Delhi, India. He specializes in cell-death research, parasitology, and therapeutic developments for infectious diseases. He has published extensively in international journals and contributed chapters to reputable publishers. He is a recipient of the INSA Medal for Young Scientist from the Indian National Science Academy and an Associate of the Indian Academy of Sciences, Bengaluru. His work has appeared in leading journals spanning infectious diseases and cellular physiology, reflecting a high scholarly impact and a broad research portfolio.